269 related articles for article (PubMed ID: 24815226)
1. Preoperative somatostatin analogs treatment in acromegalic patients with macroadenomas. A meta-analysis.
Zhang L; Wu X; Yan Y; Qian J; Lu Y; Luo C
Brain Dev; 2015 Feb; 37(2):181-90. PubMed ID: 24815226
[TBL] [Abstract][Full Text] [Related]
2. Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide.
Karavitaki N; Turner HE; Adams CB; Cudlip S; Byrne JV; Fazal-Sanderson V; Rowlers S; Trainer PJ; Wass JA
Clin Endocrinol (Oxf); 2008 Jun; 68(6):970-5. PubMed ID: 18031313
[TBL] [Abstract][Full Text] [Related]
3. Prolonged preoperative treatment of acromegaly with Somatostatin analogs may improve surgical outcome in patients with invasive pituitary macroadenoma (Knosp grades 1-3): a retrospective cohort study conducted at a single center.
Duan L; Zhu H; Xing B; Gu F
BMC Endocr Disord; 2017 Sep; 17(1):55. PubMed ID: 28874187
[TBL] [Abstract][Full Text] [Related]
4. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
Plöckinger U; Quabbe HJ
Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
[TBL] [Abstract][Full Text] [Related]
5. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.
Tolis G; Angelopoulos NG; Katounda E; Rombopoulos G; Kaltzidou V; Kaltsas D; Protonotariou A; Lytras A
Neuroendocrinology; 2006; 83(3-4):249-57. PubMed ID: 17047390
[TBL] [Abstract][Full Text] [Related]
6. Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial.
Mao ZG; Zhu YH; Tang HL; Wang DY; Zhou J; He DS; Lan H; Luo BN; Wang HJ
Eur J Endocrinol; 2010 Apr; 162(4):661-6. PubMed ID: 20061334
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly.
Ayuk J; Stewart SE; Stewart PM; Sheppard MC
J Clin Endocrinol Metab; 2002 Sep; 87(9):4142-6. PubMed ID: 12213862
[TBL] [Abstract][Full Text] [Related]
8. Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center.
Bacigaluppi S; Gatto F; Anania P; Bragazzi NL; Rossi DC; Benvegnu G; Nazzari E; Spaziante R; Giusti M; Ferone D; Zona G
Endocrine; 2016 Mar; 51(3):524-33. PubMed ID: 25982150
[TBL] [Abstract][Full Text] [Related]
9. Presurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication rates.
Losa M; Mortini P; Urbaz L; Ribotto P; Castrignanó T; Giovanelli M
J Neurosurg; 2006 Jun; 104(6):899-906. PubMed ID: 16776333
[TBL] [Abstract][Full Text] [Related]
10. Complete disappearance of a GH-secreting pituitary macroadenoma in a patient with acromegaly: effect of treatment with lanreotide Autogel and consequence of treatment withdrawal.
Auriemma RS; Galdiero M; Grasso LF; Vitale P; Cozzolino A; Lombardi G; Colao A; Pivonello R
Eur J Endocrinol; 2010 May; 162(5):993-9. PubMed ID: 20156970
[TBL] [Abstract][Full Text] [Related]
11. Long-term primary medical therapy with somatostatin analogs in acromegaly.
Su DH; Liao KM; Chen HW; Chang TC
J Formos Med Assoc; 2006 Aug; 105(8):664-9. PubMed ID: 16935768
[TBL] [Abstract][Full Text] [Related]
12. Preoperative somatostatin analogues versus direct transsphenoidal surgery for newly-diagnosed acromegaly patients: a systematic review and meta-analysis using the GRADE system.
Nunes VS; Correa JM; Puga ME; Silva EM; Boguszewski CL
Pituitary; 2015 Aug; 18(4):500-8. PubMed ID: 25261979
[TBL] [Abstract][Full Text] [Related]
13. Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study.
Shen M; Shou X; Wang Y; Zhang Z; Wu J; Mao Y; Li S; Zhao Y
Endocr J; 2010; 57(12):1035-44. PubMed ID: 21099129
[TBL] [Abstract][Full Text] [Related]
14. Outcome of multimodal therapy in operated acromegalic patients, a study in 115 patients.
Albarel F; Castinetti F; Morange I; Conte-Devolx B; Gaudart J; Dufour H; Brue T
Clin Endocrinol (Oxf); 2013 Feb; 78(2):263-70. PubMed ID: 22783815
[TBL] [Abstract][Full Text] [Related]
15. Place of preoperative treatment of acromegaly with somatostatin analog on surgical outcome: a systematic review and meta-analysis.
Pita-Gutierrez F; Pertega-Diaz S; Pita-Fernandez S; Pena L; Lugo G; Sangiao-Alvarellos S; Cordido F
PLoS One; 2013; 8(4):e61523. PubMed ID: 23634209
[TBL] [Abstract][Full Text] [Related]
16. [Outcome of somatostatin analogue treatment in acromegaly].
Mondok A; Tóth M; Patócs A; Szücs N; Igaz P; Pusztai P; Czirják S; Beko G; Gláz E; Rácz K; Tulassay Z
Orv Hetil; 2009 Aug; 150(31):1457-62. PubMed ID: 19617182
[TBL] [Abstract][Full Text] [Related]
17. Preoperative Somatostatin Analogues in Patients with Newly-diagnosed Acromegaly: A Systematic Review and Meta-analysis of Comparative Studies.
Yang C; Li G; Jiang S; Bao X; Wang R
Sci Rep; 2019 Oct; 9(1):14070. PubMed ID: 31575930
[TBL] [Abstract][Full Text] [Related]
18. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
[TBL] [Abstract][Full Text] [Related]
19. Presurgical treatment with somatostatin analogues in growth hormone-secreting pituitary adenomas: A long-term single-center experience.
Lv L; Hu Y; Zhou P; Zhang S; Yin S; Zhang N; Jiang S
Clin Neurol Neurosurg; 2018 Apr; 167():24-30. PubMed ID: 29433055
[TBL] [Abstract][Full Text] [Related]
20. Preoperative octreotide treatment of acromegaly: long-term results of a randomised controlled trial.
Fougner SL; Bollerslev J; Svartberg J; Øksnes M; Cooper J; Carlsen SM
Eur J Endocrinol; 2014 Aug; 171(2):229-35. PubMed ID: 24866574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
